Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
AssigneeSyn X Pharma, Inc.
InventorsGeorge Jackowski, Brad Thatcher, John Marshall, Jason Yantha, Tammy Vrees
Life of this patent
Estimating the term…
Abstract
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.
Claims9
A biopolymer marker peptide consisting of amino acid residues 2 to 13 of SEQ ID NO:
- 1 that is diagnostic for myocardial infarction, intracerebral hemorrhage or congestive hear failure.
A myocardial infarction diagnostic kit comprising:
- (a) a peptide consisting of amino acid residues 2 to 13 of SEQ ID NO:
- 1 and (b) an antibody that binds to said peptide in a sample from a patient.
A method for diagnosing Type II diabetes comprising:
- (a) obtaining a sample from a patient;
- (b) conducting mass spectrophotometric analysis on said sample in a manner effective to maximize elucidation of discernible peptide fragments contained therein;
- and
- (c) comparing mass spectrum profiles of a peptide consisting of amino acid residues 2 to 13 of SEQ ID NO:
- 1 to mass spectrum profiles of peptides elucidated from said sample;
- wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide of amino acid residues 2 to 10 of SEQ ID NO:
- 1 is diagnostic for myocardial infarction, intracerebral hemorrhage or congestive hear failure.
Dependencies are inferred from the claim text.